Skip to main content

WCITD_2019_NHS_EB_Abstract_Final

UK first National Health Service (NHS) Endobarrier Service for uncontrolled DIABESITY shows the metabolic improvements 6-months after Endobarrier removal are well maintained.

Authors:

REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta.

WCITD_2019_EB_Registry

Duodenal jejunal bypass liner for DIABESITY - Risk Versus benefit data from the Association of British Clinical Diabetologists (ABCD) Worldwide Endobarrier Registry.

Authors:

B. Ryder, M. Lynne, H. Frydenberg, S. Fishman, R. Cohen, C. de Jonge, J. Greve, J. Bascomb, J. Bessell, J. McMaster, G. Holtman, G. Rich, J. Collins, L. Kow, P. Pferschy, H. Sourij, J. Byrne, J. Mason, J. Teare, M. Benes.

EASD 2022 SGLT2 Slides

Sodium-glucose link transporter-2 inhibitors in reduced renal function: Cross-class comparison from the Association of British Clinical Diabetologists (ABCD) audits.

Authors:

TSJ Crabtree, A Bickerton, K Dhatariya, A Gallagher, J Elliott, R Raghavan, IW Gallen, REJ Ryder on behalf of all ABCD SGLT2 audit contributors.

EASD 2022 Semaglutide ALT Poster

The effect of semaglutide on alanine aminotransferase (ALT) levels: results from the Association of British Clinical Diabetologists (ABCD) nationwide audit.

Authors:

TSJ Crabtree, DK Sennik, A Bickerton, D Barnes, S Sivappriyan, K Adamson, SM Phillips, A Evans, N Larsen, A Panesar, ML Cull,  IW Gallen, IR Idris, REJ Ryder on behalf of all ABCD Semaglutide audit contributors